Evidence map›Paper›PMID 21056449›Full record

ArticleVirology2011

Shp2 suppresses PyMT-induced transformation in mouse fibroblasts by inhibiting Stat3 activity.

Ying Yang, Beibei Jiang, Yingqing Huo, Luca Primo, Jean S Dahl, Thomas L Benjamin, Jincai Luo

Abstract read
In one paragraph

Article in Virology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Ying YangLaboratory of Vascular Biology, Institute of Molecular Medicine, Peking University, Beijing 100871, China. yingyang76@gmail.com
Beibei Jiang
Yingqing Huo
Luca Primo
Jean S Dahl
Thomas L Benjamin
Jincai Luo
Peking University · CNHarvard University · USUniversity of Turin · IT

Funding

Tumor Host Range Mutants of Polyoma and Their TargetsR01CA092520 · NCI · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI BENJAMIN, THOMAS LIVINGSTON · 2001 to 2010
$6.0M
NCI NIH HHS R01 CA-092520NCI NIH HHS R01 CA092520
6 · The paper itself

Abstract

We have examined the effect of expression of the protein tyrosine phosphatase Shp2 on transformation by the mouse polyoma virus middle T antigen (PyMT). Gain-of-function mutations in Shp2 indicate that it may serve as an oncogene in several types of human leukemia. Paradoxically, however, some catalytically dominant-negative mutations of Shp2 have also been identified in leukemia and neuroblastomas. In this study, we show that Shp2 suppresses transformation induced by PyMT, the major polyoma viral oncoprotein known to act through binding and activation of pp60(c-src). Over-expression of a catalytically inactive Shp2 mutant in NIH3T3 cells significantly enhanced PyMT-induced transformation. Conversely, re-introduction of Shp2 into Shp2-deficient cells strongly inhibited PyMT-induced transformation and tumorigenesis. Short hairpin RNA (shRNA)-mediated Shp2 knockdown potentiated PyMT-induced transformation. Finally, we present evidence that the transformation-suppressive effects of Shp2 are mediated at least partially through the inhibition of signal transducers and activators of transcription 3.

Indexed as

Cell Transformation, NeoplasticAnimalsAntigens, Polyomavirus TransformingCell LineFibroblastsGene Knockdown TechniquesMiceMice, Inbred BALB CProtein Tyrosine Phosphatase, Non-Receptor Type 11STAT3 Transcription FactorAntigens, Polyomavirus TransformingProtein Tyrosine Phosphatase, Non-Receptor Type 11Ptpn11 protein, mouseStat3 protein, mouseSTAT3 Transcription Factor

Identifiers

PMID21056449
PMCPMC3008596
OpenAlexW1986707731

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.